Kymera Therapeutics

Discovery and characterization of potent degraders of IRAK4 and IMiD substrates for oncology indications

Read more

Discovery of IRAKIMiDs: Dual-Mechanism Degraders Targeting IRAK4 and IMiDSubstrates for Oncology

Read more

Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications

Read more

Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Read more

16th Annual International Conference on Malignant Lymphoma (ICML) Virtual Meeting, June 18 – 22, 2021

Read more

American Association of Cancer Research (AACR) 2021 Annual Meeting, April 10-15, 2021

Read more

62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition, December 5-8, 2020

Read more

62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition, December 5-8, 2020

Read more

IRAKIMiDs: A Single Small Molecule Approach to Developing Dual-Function Degraders for B Cell Lymphoma with Multiple Drivers

Read more

American Association for Cancer Research (AACR) Virtual Annual Meeting II, June 22-24, 2020

Read more